Ukr.Biochem.J. 2015; Volume 87, Issue 6, Nov-Dec, pp. 154-161


Computer prediction of biological activity of dimethyl-N-(benzoyl)amidophosphate and dimethyl-N-(phenylsulfonyl)amidophosphate, evaluation of their cytotoxic activity against leukemia cells in vitro

I. I. Grynyuk, S. V. Prylutska, N. S. Kariaka, T. Yu. Sliva,
O. V. Moroz, D. V. Franskevych, V. M. Amirkhanov,
O. P. Matyshevska, M. S. Slobodyanik

Taras Shevchenko National University of Kyiv, Ukraine;

Structural analogues of β-diketones – dimethyl-N-(benzoyl)amidophosphate (HCP) and dimethyl-N-(phenylsulfonyl)amidophosphate (HSP) were synthesized and identified by the methods of IR, 1H and 31P NMR spectroscopy. Screening of biological activity and calculation of physicochemical parameters of HCP and HSP compounds were done with the use of PASS and ACD/Labs computer programs. A wide range of biological activity of synthesized compounds, antitumor activity in particular, has been found. Calculations of the bioavailability criteria indicate that the investigated compounds have no deviations from Lipinski’s rules. HCP compound is characterized by a high lipophilicity at physiological pH as compared to HSP. It was found that cytotoxic effect of the studied compounds on the leukemiс L1210 cells was of time- and dose-dependent character. HCP is characterized by more pronounced and early cytotoxic effects as compared to HSP. It was shown that 2.5 mM HCP increased ROS production 3 times in the early period of incubation, and decreased cell viability by 40% after 48 h, and by 66% – after 72 h. Based on the computer calculation and undertaken research, HCP was selected for target chemical modifications and enhancement of its antitumor effect.

Keywords: , , , , ,


  1. Anand N. Sulfonamides and sulfones: M.E. Wolff (Ed.) Burger’s Medicinal Chemistry and Drug Discovery. Vol. 2. Therapeutic Agents.Wiley, New York, NY;1996:527-544.
  2. Slawin AMZ, Wainwright M, Woollins D. Phosphino-urea chemistry: preparation and structure of chelate and P−N bond cleavage complexes. New J. Chem. 2000; 24(2): 69-71. CrossRef
  3.  Kirsanov AV. The mechanism of the reaction of phosphorus pentachloride with a carboxylic acid amide. Izv Akad Nauk SSSR Ser Khim. 1954;4:646-655. (In Russian).
  4. Kirsanov AV, Makitra RG. The reaction of phosphorus pentachloride with a carboxylic acid amide. Trichlorphosphazoatsils. Zhurn Obshch. Khim. 1955;36:2134-2137. (In Russian).
  5. Lagunin A, Filimonov D, Poroikov V. Multi-targeted natural products evaluation based on biological activity prediction with PASS. Curr Pharm Des. 2010 May;16(15):1703-17. Review. PubMed
  6. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936-42. PubMed
  7. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 1992 Mar-Apr;5(2):227-31.  PubMed
  8. Gawryszewska P, Smolenski P. Ligands synthesis, characterization and role in biotechnology. Nova Science Publishers. New York. 2014; 295 р.
  9. Trush VA, Gubina KE, Amirkhanov VM, Swiatek-Kozlowska J, Domasevitch KV. Spectroscopic and crystal structure data of the alkali-, thallium (I) and onic- salts of dimethyl-N-trichloracetylamidophosphate. Polyhedron. 2005 Jun; 24(9): 1007-1014. CrossRef
  10.  Litsis OO, Ovchynnikov VA, Shishkina SV, Sliva TYu, Amirkhanov VM. Dinuclear 3D metal complexes based on a carbacylamidophosphate ligand: redetermination of the ligand crystal structure. Transit Met Chem. 2013 Mar; 38(4): 473 -479. CrossRef
  11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1-3): 3-25. CrossRef
  12. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002 Jun 6;45(12):2615-23. PubMed
  13. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004 Jan 12;1(1):85-96. PubMed
  14. Kerns EH, Di L. Drug-like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization. Elsevier Inc, 2008; 528 р.
  15. Liu X, Testa B, Fahr A. Lipophilicity and its relationship with passive drug permeation. Pharm Res. 2011 May;28(5):962-77. Review.  PubMed, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.